Stock Research for GCVRZ


Featured Broker: Ally Invest

Get the due diligence for another stock.


GCVRZ Stock Chart & Research Data

The GCVRZ chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GCVRZ chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GCVRZ Due diligence Resources & Stock Charts

The GCVRZ stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GCVRZ Detailed Price Forecast - CNN Money CNN View GCVRZ Detailed Summary - Google Finance
Yahoo View GCVRZ Detailed Summary - Yahoo! Finance Zacks View GCVRZ Stock Research & Analysis -

Stock Analysis

TradeIdeas View GCVRZ Trends & Analysis - Trade-Ideas Barrons View GCVRZ Major Holders - Barrons
NASDAQ View GCVRZ Call Transcripts - NASDAQ Seeking View GCVRZ Breaking News & Analysis - Seeking Alpha
Spotlight View GCVRZ Annual Report - OTC Report View GCVRZ OTC Short Report -
TradeKing View GCVRZ Fundamentals - TradeKing Charts View GCVRZ SEC Filings - Bar Chart
WSJ View Historical Prices for GCVRZ - The WSJ Morningstar View Performance/Total Return for GCVRZ - Morningstar
MarketWatch View the Analyst Estimates for GCVRZ - MarketWatch CNBC View the Earnings History for GCVRZ - CNBC
StockMarketWatch View the GCVRZ Earnings - StockMarketWatch MacroAxis View GCVRZ Buy or Sell Recommendations - MacroAxis
Bullish View the GCVRZ Bullish Patterns - American Bulls Short Pains View GCVRZ Short Pain Metrics -

Social Media Mentions

StockTwits View GCVRZ Stock Mentions - StockTwits PennyStocks View GCVRZ Stock Mentions - PennyStockTweets
Twitter View GCVRZ Stock Mentions - Twitter Invest Hub View GCVRZ Investment Forum News - Investor Hub
Yahoo View GCVRZ Stock Mentions - Yahoo! Message Board Seeking Alpha View GCVRZ Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GCVRZ - Insider Cow View Insider Transactions for GCVRZ - Insider Cow
CNBC View GCVRZ Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GCVRZ - OTC Markets
Yahoo View Insider Transactions for GCVRZ - Yahoo! Finance NASDAQ View Institutional Holdings for GCVRZ - NASDAQ

Stock Charts

FinViz View GCVRZ Stock Insight & Charts - StockCharts View GCVRZ Investment Charts -
BarChart View GCVRZ Stock Overview & Charts - BarChart Trading View View GCVRZ User Generated Charts - Trading View

Latest Financial News for GCVRZ

How Regeneron Stock Performed in the First Half of October
Posted on Friday October 19, 2018

On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12. On October 15, the company had a market capitalization of $40.08 billion. Regeneron and Sanofi (SNY) are awaiting the FDA’s decision regarding Dupixent in its asthma indication by the Prescription Drug User Fee Act (or PDUFA) date of October 20.

Novartis in Q3 2018: Analysts Expect Revenue Growth
Posted on Monday October 15, 2018

Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.

An Update on Bausch + Lomb/International in October
Posted on Monday October 15, 2018

Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth. 

Analysts’ Estimates and Ratings for Novartis in October
Posted on Thursday October 11, 2018

Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.